A new study demonstrates that dysregulation of proteostasis can be a transforming event in hematopoiesis that could prove to be therapeutically actionable for treatment of myeloproliferative neoplasms.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Marina Corral Spence/Nature Publishing Group
References
Vannucchi, A.M. et al. N. Engl. J. Med. 372, 426–435 (2015).
Kleppe, M. et al. Cancer Discov. 5, 316–331 (2015).
Deininger, M. et al. Blood 126, 1551–1554 (2015).
Osorio, F.G.S.-V. Nat. Med. 22, 91–96 (2016).
Vembar, S.S. & Brodsky, J.L. Nat. Rev. Mol. Cell Biol. 9, 944–957 (2008).
Marubayashi, S. et al. J. Clin. Invest. 120, 3578–3593 (2010).
Nangalia, J. et al. N. Engl. J. Med. 369, 2391–2405 (2013).
Klampfl, T. et al. N. Engl. J. Med. 369, 2379–2390 (2013).
Salvadó, L., Palomer, X., Barroso, E. & Vázquez-Carrera, M. Trends. Endocrinol. Metab. 26, 438–448 (2015).
Pollak, M. Nat. Rev. Cancer 8, 915–928 (2008).
Muendlein, A. et al. J. Cancer Res. Clin. Oncol. 139, 491–498 (2013).
Koppikar, P. et al. Blood 115, 2919–2927 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
LaFave, L., Levine, R. Targeting a regulator of protein homeostasis in myeloproliferative neoplasms. Nat Med 22, 20–21 (2016). https://doi.org/10.1038/nm.4028
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4028
